By Bhanvi Satija and Mariam Sunny (Reuters) -The U.S. Food and Drug Administration said on Thursday its preliminary review did not find evidence that weight-loss drugs such as Novo Nordisk’s Wegovy were tied to suicidal thoughts and the agency will continue to study the issue. Still, the FDA, which has listed suicidal thoughts as a potential safety signal for such drugs, said it could not definitively rule out that a small risk may exist due to the limited data available. Wegovy and Eli Lilly’s Zepbound belong to a class of drugs known as GLP-1 agonists, originally designed for type 2 diabetes…